SEC Comment Letter for Chewy, (CHWY) — Jan 15, 2026
Chewy, Inc.
Date: Jan. 15, 2026 · CIK: 0001766502 · Accession: 0000000000-26-000588
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 001-38936
Letter
January 15, 2026 William Billings Interim Principal Financial Officer Chewy, Inc. 7700 West Sunrise Boulevard Plantation, FL 33322 Re:Chewy, Inc. Form 10-K for Fiscal Year Ended February 2, 2025 Filed March 26, 2025 File No. 001-38936 Dear William Billings: We have reviewed your filing and have the following comment(s). Please respond to this letter within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe a comment applies to your facts and circumstances, please tell us why in your response. After reviewing your response to this letter, we may have additional comments. Form 10-K for the Fiscal Year Ended February 2, 2025 Notes to Consolidated Financial Statements Note 2. Basis of Presentation and Significant Accounting Policies Revenue Recognition, page 60 We note you generate revenue from the sale of pet products. We also note your emphasis on pet healthcare, including the provision of pharmacy, veterinary, and telehealth services. As it relates to these expanded service-based offerings, please explain your consideration of Rule 5-03(b) of Regulation S-X requiring separate presentation of revenue and costs of revenue from products, services and other revenues; ASC-606-10-50-5 and 606-10-55-89 through 55-91 requiring disclosure of disaggregated revenue recognized from contracts with customers into categories that depict how the nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factors; and ASC 280-10-50-40 requiring separate presentation of revenues from external customers for each product and service or each group of similar products and services. We also note “Other” net sales disclosed on page 43 represents approximately 19% of net sales, making it the second largest component of net sales. Please explain the composition of your Other net sales, including whether 1.
January 15, 2026 Page 2 healthcare services are being presented here. To the extent any component(s) are material consider the applicability of the aforementioned guidance. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Scott Stringer at 202-551-3272 or Adam Phippen at 202-551-3336 if you have questions regarding comments on the financial statements and related matters. Sincerely, Division of Corporation Finance Office of Trade & Services
Show Raw Text
January 15, 2026
William Billings
Interim Principal Financial Officer
Chewy, Inc.
7700 West Sunrise Boulevard
Plantation, FL 33322
Re:Chewy, Inc.
Form 10-K for Fiscal Year Ended February 2, 2025
Filed March 26, 2025
File No. 001-38936
Dear William Billings:
We have reviewed your filing and have the following comment(s).
Please respond to this letter within ten business days by providing the requested
information or advise us as soon as possible when you will respond. If you do not believe a
comment applies to your facts and circumstances, please tell us why in your response.
After reviewing your response to this letter, we may have additional comments.
Form 10-K for the Fiscal Year Ended February 2, 2025
Notes to Consolidated Financial Statements
Note 2. Basis of Presentation and Significant Accounting Policies
Revenue Recognition, page 60
We note you generate revenue from the sale of pet products. We also note your
emphasis on pet healthcare, including the provision of pharmacy, veterinary, and
telehealth services. As it relates to these expanded service-based offerings, please
explain your consideration of Rule 5-03(b) of Regulation S-X requiring separate
presentation of revenue and costs of revenue from products, services and other
revenues; ASC-606-10-50-5 and 606-10-55-89 through 55-91 requiring disclosure of
disaggregated revenue recognized from contracts with customers into categories that
depict how the nature, amount, timing, and uncertainty of revenue and cash flows are
affected by economic factors; and ASC 280-10-50-40 requiring separate presentation
of revenues from external customers for each product and service or each group of
similar products and services. We also note “Other” net sales disclosed on page 43
represents approximately 19% of net sales, making it the second largest component of
net sales. Please explain the composition of your Other net sales, including whether 1.
January 15, 2026
Page 2
healthcare services are being presented here. To the extent any component(s) are
material consider the applicability of the aforementioned guidance.
We remind you that the company and its management are responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action or absence
of action by the staff.
Please contact Scott Stringer at 202-551-3272 or Adam Phippen at 202-551-3336 if
you have questions regarding comments on the financial statements and related matters.
Sincerely,
Division of Corporation Finance
Office of Trade & Services